We assessed efficacy, safety and renal impairment (RI) reversal in untreated multiple myeloma patients treated with bortezomib-melphalan-prednisone-thalidomide followed by bortezomibthalidomide (VMPT-VT) maintenance versus bortezomib-melphalan-prednisone (VMP). Exclusion criteria included serum creatinine>2.5mg/dL. In the VMPT-VT/VMP arms, severe RI [estimated glomerular filtration rate (eGFR)<30mL/min], moderate (eGFR=31-50mL/min) and normal renal function (eGFR>50mL/min), were respectively 6%/7.9%, 24.1%/24.9% and 69.8%/67.2%.
INTRODUCTION
Renal impairment (RI) is a common feature of multiple myeloma (MM). 1, 2 At diagnosis 30% to 40% of patients with MM have serum creatinine (sCr) levels above the upper normal limit, but not exceeding 4 mg/dL in the majority of patients. [3] [4] [5] Cast nephropathy is the main cause of RI in MM (approximately 90% of cases) and reflects advanced disease and high tumour burden status. [6] [7] [8] [9] [10] RI was associated with poor prognosis in MM in the era of conventional chemotherapy and several studies demonstrated a median survival shorter than 2 years for these patients. [11] [12] [13] Early effective treatment can lead to reversibility of RI. 1, 3, 14 Moreover, patients who achieved a reversal of RI showed a prolonged survival compared to those with irreversible impairment. 3, 14 In recent years, several data support the safety and efficacy of bortezomib-based therapies in patients with myeloma with RI of any grade, with associated improvements in renal function. [15] [16] [17] [18] [19] [20] [21] [22] Limited data are available regarding the efficacy of thalidomide-based regimens in patients with MM and RI. 23, 24 To date, due to the absence of randomized results, any additional benefit of thalidomide for patients with myeloma with RI has been demonstrated and thus its use is recommended with caution and appropriate dose reduction.
Our group has recently published results of a phase III study examining the efficacy of the four-drug combination of bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) compared with VMP treatment alone in untreated MM patients ineligible for autologous stem-cell transplantation. 25 In this trial, patients with sCr level >2.5 mg/dL were excluded. Herein, we report on a cohort analysis which assesses efficacy and safety and reversal of RI for VMPT-VT vs VMP in newly diagnosed patients with MM and RI.
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PATIENTS AND METHODS

Patients and Study Design
Full details of the phase III randomized study have been published previously. 25 Patients with newly diagnosed MM ineligible for autologous stem-cell transplantation participated in the trial. Patients having sCr level >2.5 mg/dL were excluded. Experimental therapy consisted of induction with nine 6-week cycles of melphalan 9 mg/m2 on days 1-4; prednisone 60 mg/m2 on days 1-4; bortezomib 1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, 32 during cycles 1-4 and on days 1, 8, 22, 29 during cycles 5-9; and thalidomide 50 mg/day continuously. Patients received maintenance therapy with bortezomib 1.3 mg/m2 every 14 days and thalidomide 50 mg/day for 2 years or until progression or relapse. Standard VMP therapy consisted of induction therapy with nine 6-week cycles of VMP at the doses described above, without maintenance. After the inclusion of the first 139 patients, the protocol was amended to reduce the incidence of peripheral neuropathy.
Both induction schedules were changed to nine 5-week cycles and the bortezomib dose was modified to 1.3 mg/m2 on days 1, 8, 15, 22 during cycles 1-9. Progression-free survival (PFS) was calculated from the date of diagnosis to the date of progression, relapse, death for any cause or the date the patient was last known to be in remission. Duration of response (DOR) was calculated from the time of the attainment of response until the date of progression. Overall survival (OS) was calculated from the time of diagnosis until the date of death for any cause or the last follow-up. PFS and OS were analyzed for all patients, while response rates were analyzed in those patients receiving at least one cycle of study drugs. The treatment response was defined using the International Uniform Response Criteria. 26 All adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0). 27
Analysis of the Renal Cohort
In this analysis only those patients having complete monthly data for the calculation of CrCl during induction were included. Patients were subdivided by baseline estimated glomerular For personal use only. on July 15, 2017. by guest www.bloodjournal.org From filtration rate (eGFR), according to calculated creatinine clearance (CrCl) 28 and revised 29 stratification by the National Kidney Foundation Practice Guidelines for Chronic Kidney Disease. 30 Normal renal function was defined as eGFR>50mL/min and RI (eGFR<50mL/min) was subdivided into moderate (31 to 50mL/min) or severe (<30mL/min). Reversibility of RI was defined as improvement of eGFR from <50mL/min at baseline to >60mL/min following induction therapy.
Renal response was evaluated according to Ludwig 
Statistical Analysis
All statistical calculations were performed using the statistical package SPSS for Windows (v13.0, 2004 SPSS Working, Surrey, UK). Overall response rates (ORR), complete response (CR) rates and the incidence of adverse events (AEs) was compared between arms by renal cohort with the Mantel-Haenszel estimate of common odds ratio (OR) for stratified tables, with P values determined by Mantel-Haenszel χ2 test. For categorical variables, statistical comparisons were performed using two-way tables for the Fisher's exact test and multi-way tables for the Pearson's χ2 test. Survival functions were estimated using the Kaplan-Meier method and curves for categorical variables were plotted for PFS, DOR, time to RI reversal and OS. The P values for testing the differences between subgroups and levels for each variable were calculated by log-rank test. Factors associated with RI reversal were assessed by logistic univariate and multivariate analyses. Hazard ratios (HRs) for comparisons between arms by cohort were based on stratified Cox's regression analyses. A P value of <.05 was considered significant for all statistical calculations.
RESULTS
Patient Characteristics
Of the 511 patients originally allocated to the two arms, 25 complete data for the calculation of monthly CrCl during induction therapy were available for 473 patients; 232 cases were randomly assigned to VMPT-VT and 241 to VMP. Approximately 30% of patients on each arm presented with RI and most with moderate RI. In particular, 14 (6%), 56 (24.1%), and 162 (69.8%) patients receiving VMPT-VT, and 19 (7.9%), 60 (24.9%) and 162 (67.2%) receiving VMP, had eGFR<30, 31 to 50, and >50 mL/min, respectively (P=.69); 0 and 2 patients receiving VMPT-VT and VMP, respectively, had eGFR <20mL/min. Baseline demographic and disease characteristics, as well as the percentage of patients treated with bortezomib once or twice weekly were balanced between arms and respective renal cohorts (Table 1 ). However, an expected higher proportion of patients with β2-microglobulin >5.5 mg/L and International Staging System (ISS) stage III disease were included in the more severe RI group. The subgroup of VMPT-VT patients with severe RI showed a higher, although not statistically significant, rate of high risk cytogenetics compared to VMP patients with severe RI [VMPT-VT vs VMP: 5/12 (41.7%) cases vs 4/14 (28.5%); P=.4]. This study was registered at www.clinicaltrials.gov as #NCT01063179.
Efficacy
Overall, 221 and 235 patients randomly assigned to VMPT-VT and VMP, respectively, received at least one cycle of study drugs and were evaluable for response. ORR and CR rates were higher in the VMPT-VT versus VMP (ORR, OR=2.8, P=.001; CR rate, OR=1.9, P=.002) ( OR=2.1, P=.3; CR rates, OR=3.0, P=.2). Within the VMPT-VT and VMP arms, ORR and CR rates appeared similar between renal cohorts. Median time to first response appeared similarly rapid in both arms and was not influenced by renal function ( Table 2) .
Although a significantly longer DOR was observed in patients treated in the VMPT-VT arm (HR 1.5, 95% C.I. 1.1-2.1, P=.033), this difference was no longer statistically significant when cases were categorized with respect to both treatment arm and renal function ( Table 2 ).
Furthermore, within the VMPT-VT and VMP arms RI did not influence the DOR.
One hundred and fifty-two of the 473 (32%) patients progressed, with the median PFS for the entire population being 31 months. Patients treated with VMPT-VT showed a better PFS than those with VMP (HR 1.6, 95% C.I. 1.2-2.3, P=.003), even when patients were re-grouped into those without (HR 1.5, 95% C.I. 1.1-2.3, P=.029) or with RI (HR 1.9, 95% C.I. 1.1-3.5, P=.043) ( Figure   1 ). However, this advantage in favour of VMPT-VT was only observed in patients with moderate RI (HR 2.1, 95% C.I. 1.1-4.3, P=.033), but not in those with severe RI (HR 0.9, 95% C.I. 0.2-3.6, P=.9). No difference was seen within the two arms across renal cohorts of patients.
After a median follow-up of 21.6 months, 40 patients died and the 1-year and 2-year OS rates were similar in the two treatment arms ( Table 2) . No difference in terms of OS was observed when cases were clustered with respect to both treatment arm and renal function ( Figure 2A ).
Notably, within the VMPT-VT arm, a statistically significant shorter OS was observed in patients with severe than those with moderate RI (2-year OS probability: VMPT-VT patients with eGFR 31-50 mL/min versus VMPT-VT patients with eGFR<30 mL/min, 89.6% versus 60.2% respectively; P=.016) ( Figure 2B ). While, in contrast, no differences were observed within the VMP arm (2-year OS probability: VMP patients with eGFR=31-50 mL/min versus VMP patients with eGFR<30 mL/min, 88.7% vs 83.3% respectively; P=.5) ( Figure 2B ). No statistically different OS was observed between the two arms among patients with severe RI (2-year OS probability: VMPT-VT For personal use only. on July 15, 2017. by guest www.bloodjournal.org From patients with eGFR<30 mL/min vs VMP patients with eGFR<30 mL/min, 60.2% vs 83.3% respectively; P=.25). Although there was a trend for a higher rate of renal improvement in the VMP arm, times to renal impairment reversal were not significantly different in patients treated with VMPT-VT versus VMP ( Figure 3 ). Among patients achieving RI reversal, median time to reversal was 2.3 months (range 0.5-12) and 2.2 months (range 0.4-10) for VMPT-VT and VMP arms, respectively. Among several factors potentially affecting the rate of RI reversal other than the trial arm (i.e. bortezomib once versus twice weekly, age, β2-microglobulin, albumin and LDH serum levels, cytogenetic risk, response to therapy, performance status, the severity of RI, sex), only male sex (OR=0.4, P=.016) and eGFR>30mL/min (OR=0.1, P=.004) significantly predicted RI reversal (Table 3 ). By logistic multivariate analysis, male sex (RR=0.4, 95% C.I.=0.2-0.9, P=.022) and moderate RI (RR=0.01, 95% C.I.=0.02-0.4, P=.003) significantly predicted renal function recovery ( Table 3 ). The treatment arm did not influence the RI reversal by univariate and multivariate analyses. Patients achieving RI reversal did not show any statistically different ORR, time to first response, DOR and PFS than those who did not, while OS was significantly shorter for patients who failed to recover from RI (P=.048) ( Figure 4A ). Notably, 0/4 and 5/17 cases (P=.53) with RI who did not respond to VMPT-VT or VMP showed RI reversal. Within the VMPT-VT and VMP arms median time to first For personal use only. on July 15, 2017. by guest www.bloodjournal.org From response, as well as DOR and PFS were not influenced by RI reversal. Interestingly, OS curves were significantly different between patients achieving a renal response or those who did not, only in the VMP arm ( Figure 4B ).
Reversal of Renal Impairment
Safety
All renal cohorts received a median of 9 treatment cycles, while those treated with VMPT having eGFR<30mL/min received a median of 7.5 cycles. The proportion of patients requiring treatment interruption for AEs was higher in the VMPT-VT group (P=.026), while within the two arms the presence or absence of RI did not affect the discontinuation rate for AEs (VMPT-VT: P=.37; VMP: P=.65).
No statistically different rates of grade 3/4 hematological and non-hematological AEs or of treatment discontinuation were observed between the subgroups of patients with moderate or severe RI within the two treatment arms ( Table 4 ). The proportion of cases requiring therapy discontinuation for AEs was significantly higher in VMPT-VT patients with moderate RI than in VMP patients with moderate RI (Table 4) . A significantly higher rate of grade 3/4 episodes of neutropenia was observed in patients with severe RI treated with VMPT-VT than those with severe RI treated with VMP (Table 4 ).
Patients achieving RI reversal had a slight improvement of safety profile than those with irreversible impairment (grade 3/4 hematologic AEs >3: 60.9% vs 54.3%, P=.49), with an expected trend towards a reduction in the rate of anemia in patients with recovery of renal function (10.9% vs 25%, P=.052).
DISCUSSION
Recent data from our phase III randomized trial explored the potential synergies of a rational 4-drug combination (VMPT), followed by VT maintenance, with the standard VMP with no maintenance therapy. 25 Herein, we report the analysis of the renal subgroups of this trial, assessing the activity, tolerability, and impact on RI reversal of VMPT-VT versus VMP.
In our study, the response indicators were significantly better in the VMPT-VT versus VMP arms in patients with normal renal function (eGFR>50mL/min) and in those with RI (eGFR<50mL/min). In line with our recently published efficacy results, 25 the analysis of this renal cohort showed that VMPT-VT is superior to VMP in terms of ORR, CR rates, DOR and PFS in untreated MM patients ineligible for autologous stem-cell transplantation with RI. The overall efficacy of both regimens seems not to be substantially influenced by RI, since ORR, CR rates, DOR and PFS results overlapped across patients with or without RI within both arms. Moreover, no difference in terms of OS was observed subdividing patients by treatment and renal function. This is a general finding also underscored by the VISTA trial, in which bortezomib-based therapy showed a good efficacy in untreated and relapsed/refractory patients with RI [15] [16] [17] [18] 32 including those requiring dialysis. [15] [16] [17] [18] 20, 21, [31] [32] [33] [34] [35] [36] [37] In addition, the rapidity of response, an important end-point for patients with RI, was not influenced by renal function in both arms.
However, when patients were analyzed according to degree of RI, VMPT-VT remained statistically superior to VMP in terms of ORR and PFS only in the moderate RI subgroup, but not in those with severe RI. In this small cohort, differences between VMPT-VT and VMP in terms of ORR, CR rates, PFS and OS did not reach statistical significance, probably due to limited patient numbers. Notably, within the VMPT-VT arm, patients with severe RI showed a shorter OS than the other renal subgroups, probably reflecting coexistence of adverse factors. In particular, VMPT-VT cases with severe RI received fewer cycles of chemotherapy than others (7.5 vs 9 cycles) and had a higher rate of unfavorable cytogenetics, moreover none of these achieved a RI reversal. The small
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From number of cases in the severe RI subgroups did not allow to definitively conclude whether the addition of thalidomide to VMP worsens outcome in patients with severe RI.
The safety profile of both arms appeared only somewhat influenced by RI. Although in patients with eGFR<50mL/min the rates of grade 3/4 hematologic AEs appeared statistically higher compared to patients with higher eGFR, the median number of cycles administered and the rate of discontinuation to AE were similar between patients with normal renal function and RI within the two arms. This is in line with other reports in which renal function did not influence the safety of bortezomib therapy. [15] [16] [17] 32 Similarly to the VISTA trial, 19 the VMP safety profile appeared to be moderately affected by RI, while in contrast, we observed slightly less hematological AEs. This phenomenon could be due to the weekly administration of bortezomib adopted in roughly 75% of our patients as a result of the amended protocol.
In the VMPT-VT and VMP arms the rates of RI reversal were 25.4% and 40.3%, respectively; notably, for those patients with eGFR<30 mL/min, the rate of RI reversal was 0% in the VMPT-VT arm and 11% in the VMP arm. Data of RI reversal in the VMP arm are in line with those showed in the VISTA trial (40%). 19 Other studies of bortezomib-based regimens have also reported similar notable levels of RI reversal. 18, [20] [21] [22] 33, 34, 36, 37 Differently from the VISTA trial, 19 in which advanced age together with an abnormal renal function (eGFR<30mL/min) represented negative factors for RI recovery, in our study logistic multivariate analysis indicated male sex, but not age, as predictors of renal function recovery, while the moderate RI was confirmed as an independent prognostic factor also in our series. However, it is interesting to note that both the rate of and the time to RI reversal did not differ significantly in the two arms. These findings indicate that the addition of thalidomide does not improve the results achieved with VMP in patients with RI, in terms of recovery of renal function. Nevertheless, Kastritis et al observed RI reversal with thalidomide and high-dose dexamethasone, with or without bortezomib, in 80% of previously untreated patients. 24 However, the latter study clearly demonstrated the crucial role of high-dose
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From dexamethasone for obtaining high rates of renal function reversal, when combined with either the older or the newer drugs. 24 Interestingly, as reported in the VISTA trial 19 and in other studies, 3, 34 only a few cases in the VMP arm achieved renal response without a MM response, suggesting that even minor reductions in tumor burden may be associated with reversal of RI; one reason may be that bortezomib has a direct effect on renal function. 5 Finally, cases that reversed RI experienced a slight improvement of safety profile compared with those with irreversible impairment. OS was significantly shorter for those patients who failed to recover from RI and more interestingly, OS curves diverged significantly in the VMP but not in the VMPT-VT arm. This difference in OS may reflect more advanced disease in patients with RI that seems to be rescued by the addition of thalidomide to the VMP treatment regimen.
In conclusion, this cohort analysis reflects the overall efficacy of VMPT-VT resulting from our recently published phase III randomized trial, remaining superior to VMP for moderate RI patients. As can been deduced, VMPT-VT failed to outperformed VMP in patients with severe RI.
Nonetheless, drawing definitive conclusions regarding this combination schedule in severe RI patients is precluded due to the fact that the protocol was not designed to demonstrate this issue since patients with sCr level >2.5 mg/dL were excluded from the study and consequently the severe RI cases included in this analysis are limited. Finally it seems that VMPT-VT patients with severe RI show a higher, although not significant, rate of high risk cytogenetics.
The safety of both therapy arms is not substantially influenced by the degree of RI in our analysis but a higher rate of severe hematologic AEs was observed presumably due to the effect of mephalan. Moreover, the addition of thalidomide to VMP did not impact on RI reversal. Thus we can conclude that the use of VMPT-VT as a treatment can be justified outside of a clinical trial in cases with normal or moderately abnormal renal function, with bortezomib-based therapy overall showing a favorable effect in patients with both moderate and severe RI. For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
